6,7-oxygenated steroids and uses related thereto
Abstract
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6alpha and 7beta oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6alpha and 7beta oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and delta-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
Term
Term ended
Projected expiry passed 11 July 2017, 9.2 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
29 members in 14 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 2345096 | United States of America | P | |
| 67964296 | United States of America | A | |
| 9700490 | Canada | W |
Members29
| Document | Office | Kind | |
|---|---|---|---|
| CA2259981A1 | Canada | A1 | |
| WO9802450A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU3332397A | Australia | A | |
| EP0917534A2 | European Patent Office (EPO) | A2 | |
| CN1222159A | China | A | |
| BR9710353A | Brazil | A | |
| US6046185A | United States of America | A | |
| KR20000023661A | Republic of Korea | A | |
| AU722815B2 | Australia | B2 | |
| NZ333731A | New Zealand | A | |
| JP2001503732A | Japan | A | |
| EP0917534B1 | European Patent Office (EPO) | B1 | |
| AT229031T | Austria | T | |
| ATE229031T1This record | Austria | T1 | |
| RU2196143C2 | Russian Federation | C2 | |
| DE69717633D1 | Germany | D1 | |
| EP1304333A2 | European Patent Office (EPO) | A2 | |
| ES2187788T3 | Spain | T3 | |
| DE69717633T2 | Germany | T2 | |
| US6706701B1 | United States of America | B1 | |
| US2004157814A1 | United States of America | A1 | |
| US2004162425A1 | United States of America | A1 | |
| EP1304333A3 | European Patent Office (EPO) | A3 | |
| US6949533B2 | United States of America | B2 | |
| KR100533436B1 | Republic of Korea | B1 | |
| US7067682B2 | United States of America | B2 | |
| US2006211857A1 | United States of America | A1 | |
| CN100368425C | China | C | |
| CA2259981C | Canada | C |
2 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Ceased due to non-payment of the annual feeCeasedREN | REN | |
| Publication of translation of european patent specificationUEP | UEP |
Numbers
- Application
- 97929071
Titles2
- German
- 6,7-OXYGENIERTE STEROIDE UND DEREN VERWENDUNG
- English
- 6,7-OXYGENATED STEROIDS AND THEIR USE
Classification
- CPC, 17
- C07J9/00
- C07J1/00
- C07J1/0007
- C07J1/0011
- C07J1/0022
- C07J3/00
- C07J7/002
- C07J13/005
- C07J13/007
- C07J17/00
- C07J21/008
- C07J31/006
- C07J41/0016
- C07J51/00
- C07J71/001
- C07J71/0026
- Y02P20/55
- IPC, 12
- A61K31 56
- C07J1 00
- C07J3 00
- C07J7 00
- C07J9 00
- C07J13 00
- C07J17 00
- C07J21 00
- C07J31 00
- C07J41 00
- C07J51 00
- C07J71 00